AstraZeneca announced that baxdrostat, a selective aldosterone synthase inhibitor, met its primary and all secondary ...

Baxdrostat is an investigational highly selective, oral, small molecule designed to inhibit aldosterone synthase.

Baxdrostat, which AstraZeneca acquired in a 2023 buyout of CinCor Pharma, could become a new treatment for people whose ...

At two doses, baxdrostat demonstrated significant reduction in mean seated systolic BP vs. placebo at 12 weeks among patients ...

The money will focus on a manufacturing plant in Virginia that will make the company's weight management and metabolic drugs ...

AstraZeneca Plc’s experimental hypertension drug Baxdrostat reduced the blood pressure of patients who have an uncontrolled ...

As President Donald Trump’s tariff policies loom, global pharmaceutical giant AstraZeneca will invest $50 billion to boost ...

AstraZeneca, the U.K.-Swedish pharmaceutical giant, on Tuesday announced a plan to invest some $50 billion in the U.S. in a ...

Positive high-level results in trials of its baxdrostat drug to treat hypertension provided AstraZeneca shares with a ...

AstraZeneca said on Monday its experimental drug baxdrostat significantly lowered blood pressure in a late-stage trial of ...

NEW ORLEANS — Baxdrostat, an aldosterone synthase inhibitor, did not lower systolic BP compared with placebo at 8 weeks in patients with uncontrolled hypertension, but nonadherence may have been ...